Small node negative HER2 Positive tumors are defined as T1 (<2 cm) and N0 (node negative). The above cohort is increasing with more awareness and acceptance of
mammography screening. This group in itself is a heterogeneous population such as
T1a/b versus T1c, Grade I versus II/III and estrogen receptor (ER) positive versus
negative tumours. The role of adjuvant therapy for these women is a long-standing
dilemma for clinicians due to the lack of prospective randomized trials and a poor
representation of this group in pivotal trials. Even guidelines are inconsistent on
chemotherapy regimen and the duration of trastuzumab for this subset.
There is increasing evidence from several retrospective studies for an inferior outcome
in these patients with recurrence rates as high as 15%–30% after 5–10 years.[1] In a British Columbia data set [2] of N0 breast cancers, positive HER2 status was an independent predictor of breast
cancer death in 10 years in a multivariable model, with odds ratio (OR) of 2.03 (P = 0.003) and in a European Institute of Oncology [3] population of pT1abN0 breast cancers, it was an independent predictor of 5 years
disease-free survival (DFS) with OR of 2.5 (95% confidence interval [CI]: 0.9-6.5;
P = 0.09). The available evidence for the efficacy of trastuzumab for these patients
has limitations such as subgroup analysis of large randomized trials, retrospective
nature, small numbers, few events in trials, and differing end points or durations
of follow up. Five large randomized Phase III multicenter studies have shown that
the addition of trastuzumab to chemotherapy results in decreased recurrence and better
overall survival (OS). The proportion of TIN0 tumors and their survival outcome (subgroup
analyses) compared to the overall group is depicted in [Table 1].
Table 1
Drugs used in various treatment protocols used to treat acute lymphoblastic leukemia
|
Study
|
Patient population
|
n
|
ER+ and or PgR positive (%)
|
Node negative (%)
|
pT 1 tum (%)
|
HR for DFS (95% CI)
|
HR for OS (95% CI)
|
|
HR given for the additional benefit for adjuvant trastuzumab compared with no such
treatment. HR – Hazard ratio; CI – Confidence interval; DFS – Disease-free survival;
OS – Overall survival; ER – Estrogen receptor; ACTH – Docetaxel and trastuzumab
|
|
HERA[4]
|
HER2+N + HER2+ N- >pT1b
|
3387
|
45
|
32
|
40
|
Overall: 0.54 (0.43-0.67) N-tum 0.51 (0.30-0.87)
|
0.76 (0.47-1.23)
|
|
Fin Her[2]
[5]
|
N+ N- and >pT1c and PgR <10%
|
1010
|
72
|
11
|
44
|
0.42 (0.21-0.83)
|
0.55 (0.27-1.11)
|
|
Intergroup N9831, NSABP-B31[4]
[6]
[8]
|
HER2+ N + HER2+ N+ >pT1c ER + HER2+ N- >Pt1b ER-
|
3969
|
52
|
6
|
39
|
0.49 (0.41-0.58)
|
0.62 (0.49-0.81)
|
|
BCIRG 006[7]
|
HER2+ N+ HER2+N- and risk factors
|
3222
|
54
|
29
|
40
|
Overall; 0.49 (ACTH), 0.61 (TCH) N-negative tumors: 0.32 (0.17-0.62) Pt1c tumors:
0.6 (0.4-1.0)
|
0.63 (0.48-0.81) for ACTH: 0.77 (0.60-0.99) for TCH
|
|
PACS-04[8]
|
HER2+ N+
|
3010
|
10
|
None
|
32
|
0.86 (0.61-1.22)
|
1.27 (0.68-2.38)
|
Deescalation of Chemotherapy
The APT trial [9] was the first prospective investigation of a reduced intensity adjuvant treatment
regimen (weekly paclitaxel and trastuzumab [TH] for 12 weeks, followed by completion
of 1 year of trastuzumab [H]) in small, node-negative HER2+ disease following standard
breast surgery. Majority of the patients in this trial were T1N0 with 8.9% of these
had T size 2–3 cm. Survival free from invasive disease, the primary end point of the
trial, was 98.7% (95% CI: 97.7%–99.8%) at 3 years, supporting TH as a highly effective
regimen in this patient population. Another prospective, single-arm Phase II trial
[10] has looked at a more intensive regimen in early stage HER2+ breast cancer. In this
trial, patients were treated in the adjuvant setting with four cycles of docetaxel/cyclophosphamide/trastuzumab,
followed by every 3 week trastuzumab to complete a year of therapy. The primary endpoint
was DFS at 2 years, but follow-up was long enough to calculate 3-year survival estimates.
Overall 3-year DFS and OS were 96.9% and 98.7%, respectively. Among node-negative
patients with primary tumor size less than or equal to 1 cm, 3-year DFS and OS were
both 100%.
Deescalation of Trastuzumab Duration
Adjuvant trastuzumab is approved across the globe for 1 year duration as standard
treatment. There have been attempts at reducing this duration [Table 2]. The arguments for a shorter duration of exposure may be supported by cardiac safety
and cost effectiveness and especially relevant for this subset of patients.
Table 2
Trials looking at shorter duration trastuzumab
|
PHARE – Protocol of Herceptin Adjuvant with Reduced Exposure
|
|
9 weeks versus 12 months
|
|
Sold
|
|
Doc + Tras → FEC
|
|
Doc + Tras → FEC → Tras
|
|
Short-HER
|
|
EC/AC → Doc + Tras → Tras
|
|
Doc+Tras → FEC
|
|
6 months versus 12 months
|
|
Persephone-sequential
|
|
Chemotherapy → Tras
|
|
Chemotherapy → Tras
|
|
Persephone-concurrent
|
|
Doc + Tras → FEC → Tras
|
|
Doc + Tras → FEC → Tras
|
|
PHARE
|
|
Chemotherapy → Tras
|
|
Chemotherapy → Tras
|
|
Hellenic
|
|
FEC → Doc + Tras → Tras
|
|
FEC → Doc + Tras → Tras
|
FINHER approach reported by Joensuu et al.[5] showed that a brief course of trastuzumab administered concomitantly with docetaxel
is safe and effective, but the study cohort included patients who were either node
positive or had T size> 2 cm high-risk node negative tumors. The Protocol of Herceptin
Adjuvant with Reduced Exposure trial [11] evaluated the efficacy of 6 versus 12 months of trastuzumab treatment. In this noninferiority
trial, 3400 patients who had started trastuzumab were randomly assigned at 6 months
to complete the standard 12 months of therapy or to stop therapy at the 6-month time
point. The 95% CI hazard ratio (HR) for noninferiority was set at 1.15. However, 6
months of trastuzumab did not meet this threshold, with an HR of 1.28 (P = 0.029). Of note, although statistical noninferiority of 6-month duration was not
established, the absolute benefit of longer duration in DFS and OS was small. Subsequently,
a subgroup analysis of this study was published. In this analysis, there was a suggestion
that in patients with very low risk (T <2 cm and N0) and low-risk (T ≤2 cm or 1–3
nodes) 6 months and 12 months of trastuzumab did not result in markedly different
outcomes.[12] Hellenic Oncology Research Group conducted a randomized study to compare the efficacy
of 12 versus 6 months of adjuvant trastuzumab administered concurrently with dose-dense
chemotherapy in women with node-positive or high-risk node-negative early breast cancer.
Although this trial also failed to demonstrate the noninferiority of 6 versus 12 months
administration, it had many limitations such as small sample size and a relatively
high noninferiority margin of 8%.[13] Results of other trials of shorter trastuzumab duration are forthcoming.
The proposed schema for Adjuvant therapy of Stage 1 HER2+ breast cancer is shown in
[Figure 1].
Figure 1: Proposed schema for adjuvant therapy of Stage 1 HER2+ breast cancer
In summary, both retrospective and meta-analysis data suggest a benefit to trastuzumab
treatment in small and/or node-negative HER2+ tumors. The questions of “how low and
how much” and tumor size thresholds remain open to debate. Available data also suggests
that, although durations shorter than 1 year are not clearly noninferior to 1 year
of adjuvant trastuzumab, the absolute benefits of longer duration are small and may
not exist in small, node negative tumors. Thus, durations shorter than 1 year may
be appropriate in resource constrained settings. The potential role of novel HER2
directed therapies in this cohort is not clear. Greater integration of translation
research and gene signatures may provide further insight for this subset in the future.
